Consultations are
available at the nearest clinic of
Cosmetic Surgery Seishin.
- April 1, 2012
- The Seishin Regeneratice Medicine was established at Yokohama, Nagoya and Hiroshima Clinic in April 2012. The Celution System has already been introduced into seven clinics in Japan.
- April 27, 2010
- StemSource® stem cell bank introduced for the first time in Japan (for cryopreservation of adipose tissue-derived stem cells)
- April 20, 2010
- Regenerative Therapy with Growth Factors, the world’s most advanced treatment for hair regeneration
- April 5, 2010
- Testimonial issued to our clinic for our scientific achievements in stem cell transplantation
- Home
- >
- New Information
Following the Tokyo,Osaka and Fukuoka Clinics, the Yokohama, Nagoya and Hiroshima Clinic also started regenerative medicine by transplantation of adipose tissue-derived stem cells.
Cosmetic Surgery Seishin (Seishin Regenerative Medicine Tokyo) has recently introduced StemSource® stem cell bank, Japan’s first cryopreservation service for adipose tissue-derived stem cells.
Our clinic has recently introduced Regenerative Therapy with Growth Factors, a treatment for hair regeneration on the basis of the world’s most advanced regenerative medicine technology.
The American Academy of Cosmetic Surgery (AACS) considered our efforts to perform stem cell transplantation as scientific achievements in the field of cosmetic medicine and gave us a testimonial.
Three American cosmetic surgeons came to Japan to see our regenerative medicine technologies and facilities. On the day of the visit, General Director Kamakura gave a presentation on the transplantation of adipose tissue-derived stem cells and regenerative medicine, and they actively exchanged information on stem cells.
Actively engaging in international exchanges in cosmetic medicine, we recently participated in joint technical training with physicians in Thailand, France, South Korea, and Poland.
We have introduced Skin Cell Regeneration Therapy, a type of regenerative medicine in which cultured skin cells (fibroblasts, collagen) are returned to the skin to rejuvenate skin functions. We have also started a banking (storage) service in which your young cells are stored frozen for use in treatment in the future.
Seven physicians at DNA Clinic LAb in the Kingdom of Thailand came to Japan and exchanged information on regenerative medicine with General Director Kamakura.
Following the Tokyo, Osaka, and Fukuoka Clinics of Cosmetic Surgery Seishin, the Seishin Regenerative Medicine will be established in Sapporo in mid-March 2009. The new center provides Celution breast augmentation, or transplantation of adipose stem cells with the Celution System.
This November, General Director Kamakura was invited to lecture at the University of California, San Diego, (UCSD) in the United States. In addition, he exchanged information on medical technology with Steven R. Cohen, MD, an authority on plastic surgery in America. He then visited the US head office of Cytori Therapeutics, Inc., a developer of the Celution System, to inspect the manufacturing process and to have a meeting for improvement of quality and technology.
Recently granted was a US patent for the CelutionSystem, which our clinics use for harvesting stem cells in breast augmentation and anti-aging treatment by transplantation of adipose tissue-derived stem cells.
The Celution System has already been introduced into three clinics in Japan.
Following the Tokyo and Osaka Clinics, the Fukuoka Clinic also started regenerative medicine by transplantation of adipose tissue-derived stem cells.
Breast augmentation by transplantation of adipose tissue-derived stem cells was featured in The Wall Street Journal on August 19, 2008. This article described breast reconstruction and breast augmentation by transplantation of stem cells, the Celution System, and testimonials of patients undergoing Celution Breast Augmentation in our clinics.
■The Wall Street Journal
A daily journal specializing in economics published by Dow Jones & Company in New York, United States.
Circulation: About 2 million copies
The detailed information of Celution Breast Augmentation is this
The establishment of Seishin Regenerative Medicine Tokyo last November was followed by the establishment of the Regenerative Medicine Center at the Cosmetic Surgery Seishin Osaka Clinic (Umeda, Osaka) in May 2008. Now, the Tokyo Clinic and the Osaka Clinic provide regenerative medicine-based treatment, including Celution Breast Augmentation by transplantation of adipose tissue-derived stem cells with the Celution System.
US Cytori Therapeutics, Inc. (San Diego, CEO Christopher J. Calhoun), the company developing the Celution System, a high-precision device for extraction of stem cells, won two categories of the Frost & Sullivan Awards/Innovation of the Year 2008, which are known to be the highest honors awarded by the American health care industry.
Along with the establishment of the Seishin Regenerative Medicine, press conference was held at the Hotel Mandarin Oriental Tokyo (Chuo-ku, Tokyo).
- Details of press conference:
- Establishment of Seishin Regenerative Medicine at the Cosmetic Surgery Seishin Tokyo Clinic and transplantation of adipose tissue-derived stem cells
- Date:
- November 6 (Tue), 2007
・18:00: Press conference
・19:00: Press reception - Place:
- Linden Room, Hotel Mandarin Oriental Tokyo
■Participating panelists
- Tatsuro Kamakura（General Director of Cosmetic Surgery Seishin, Director of Seishin Regenerative Medicine）
- Marc Hedrick（President of Cytori Therapeutics, Inc.）
- Christopher Calhoun（CEO of Cytori Therapeutics, Inc.）
- Keizo Sugimachi（Professor Emeritus at Kyushu University, Director of Kyushu Central Hospital）
- Masumi Miyazaki（Actress）
- Eiko Uchida（President of NPO Bougainvillea）
- Yuji Tominaga（Chief Medical Officer of Beluga Clinic）
- The world’s first breast augmentation with the use of the Celution System
- Fully automated accurate procedure for extraction of stem cells to solve problems associated with conventional breast augmentation
- Application of regenerative medicine technology for the establishment of anti-aging medicine on the basis of the patient’s own tissue and potential for self-renewal
Tatsuro Kamakura, the general director of Cosmetic Surgery Seishin, established the Seishin Regenerative Medicine at the Cosmetic Surgery Seishin Tokyo Clinic and performed the world’s first breast augmentation by transplantation of adipose tissue-derived stem cells with the use of the CelutionTM System (a medical device for accurate extraction of stem cells from adipose tissue) in the field of cosmetic medicine at the center on Tuesday, November 6, 2007.
In cooperation with the American biotechnology venture Cytori Therapeutics, Inc., Seishin Regenerative Medicine will enroll 20 women in a joint clinical study of tissue augmentation with adipose tissue-derived stem cells harvested with the Celution System (Cytori Therapeutics, Inc.).
Breast augmentation by transplantation of adipose tissue-derived stem cells is a technology that solves the problems associated with conventional breast augmentation. Common procedures for fat injection have a graft survival of about 30% to 50% after absorption of the majority of injected fat into the body and may be associated with calcification, lump formation, and fat necrosis. In contrast, transplantation of adipose tissue-derived stem cells is expected to allow prolonged retention of transplanted fat with a graft survival of about 70% to 80%. In addition, the use of the Celution System allows extraction of stem cells with more consistent purification of the stem cell concentrate resulting in greater purity and higher quality in a shorter time than manual extraction of stem cells.
After the introduction of the technology, Seishin Regenerative Medicine at Cosmetic Surgery Seishin expanded the system for application and widespread use of the technology in breast reconstruction and cosmetic medicine (breast augmentation) in cooperation with a group led by Dr. Keizo Sugimachi, professor emeritus at Kyushu University and a pioneer in Celution System-based transplantation of adipose tissue-derived stem cells for breast reconstruction in patients with breast cancer. Our efforts come from an increase in the number of patients with breast cancer and resulting increase in breast conserving surgeries in Japan. For women, breast deformation is highly stressful and associated with emotional distress. To help patients relieve the emotional distress of a mastectomy for breast cancer and experience the joy of living is consistent with the treatment policy of Cosmetic Surgery Seishin, that is, to provide cosmetic medicine for improvement in the QOL. Through clinical application of regenerative medicine technologies, primarily technology for transplantation of adipose tissue-derived stem cells, we work to establish anti-aging medicine on the basis of autologous tissue and self-healing potential.
